Analysis of the clinical efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with type 2 diabetes mellitus

Cover Page

Cite item

Full Text

Abstract

The article presents data on the analysis of the clinical efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease (COPD) in combination with type 2 diabetes mellitus during a 5 years follow-up period.

Materials and methods. The study included patients (n=103) with COPD in combination with type 2 diabetes. Primary endpoints were changes dyspnea mMRC score, FEV1, number of exacerbations of COPD, hospitalizations, and a rate of pneumonia. The prognostic indices BODE, DOSE, ADO were also calculated. 13-valent conjugate pneumococcal vaccine PCV-13 and 23-valent polysaccharide vaccine PPV-23 were used for vaccination.

Results. It has been established that when vaccination is included in the management plan for patients with COPD in combination with diabetes, the severity of dyspnea decreases, the lung function stabilize both for short-term and 5-years follow-up. Vaccination with PCV-13 and PPV-23 reduce number of exacerbations, a rate of pneumonia and hospitalizations, but long-term efficacy has been demonstrated only for PCV-13. Vaccination with PCV-13 can improve the quality of life and prognosis for patients with COPD in combination with type 2 diabetes.

Conclusion. Vaccination of pneumococcal infection in patients with COPD and type 2 diabetes mellitus can reduce the number of exacerbations, incidence of pneumonia and the number of hospitalizations, improve the prognosis and survival of patients using PCV-13 by maintaining efficacy for 5 years of follow-up.

About the authors

Galina L. Ignatova

South Ural Sate Medical University

Email: blinel@mail.ru
ORCID iD: 0000-0002-0877-6554

д-р мед. наук, проф., зав. каф. терапии Института дополнительного профессионального образования

Russian Federation, Chelyabinsk

Elena V. Blinova

South Ural Sate Medical University

Author for correspondence.
Email: blinel@mail.ru
ORCID iD: 0000-0003-2507-5941

канд. мед. наук, доц. каф. терапии Института дополнительного профессионального образования

Russian Federation, Chelyabinsk

Vladimir N. Antonov

South Ural Sate Medical University

Email: blinel@mail.ru
ORCID iD: 0000-0002-3531-3491

д-р мед. наук, проф. каф. терапии Института дополнительного профессионального образования

Russian Federation, Chelyabinsk

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. 2021 Report. Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed: 01.10.2020.
  2. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397-412. doi: 10.1183/09031936.06.00025805
  3. World Health Organization. Projections of mortality and causes of death, 2016 and 2060. Available at: http://www.who.int/healthinfo/global.burden.disease/projections/en/ Accessed: 01.10.2020.
  4. International Diabetes Federation. Diabetes Atlas 9th Edition. 2019. Available at: https://www.diabetesatlas.org/upload/resources/material/ Accessed: 01.10.2020.
  5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск. М., 2021 [Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. Dedova II, Shestakovoi MV, Mayorovoi AYu. 10th ed. Moscow, 2021 (in Russian)]. doi: 10.14341/DM12802
  6. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33(1):55-60. doi: 10.2337/dc09-0880
  7. Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. Eur Respir Soc. 2013;59:117-34.
  8. Российское респираторное общество. Клинические рекомендации: Хроническая обструктивная болезнь легких. М., 2021 [Rossiiskoe respiratornoe obshchestvo. Klinicheskie rekomendatsii: Khronicheskaia obstruktivnaia bolezn' legkikh. Moscow, 2021 (in Russian)].
  9. Авдеев С.Н. Обострение ХОБЛ: значение инфекционного фактора и антибактериальная терапия. РМЖ. 2003;22:1205 [Avdeev SN. Exacerbation of COPD: the importance of the infectious factor and antibacterial therapy. RMZh. 2003;22:1205 (in Russian)].
  10. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8-11. doi: 10.1513/pats.200404-032MS
  11. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71-9. doi: 10.1136/thx.2009.129502
  12. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. doi: 10.1093/ofid/ofu024
  13. Игнатова Г.Л., Антонов В.Н. Пятилетний анализ эффективности вакцинации пневмококковой инфекции у пациентов с хронической обструктивной болезнью легких. Пульмонология. 2018;28(2):185-92 [Ignatova GL, Antonov VN. Efficacy analysis of five-year experience of vaccination with conjugate pneumococcal vaccine in patients with chronic obstructive pulmonary disease. Pulmonologiya. 2018;28(2):185-92 (in Russian)]. doi: 10.18093/0869-0189-2018-28-2-185-192
  14. Игнатова Г.Л., Блинова Е.В., Антонов В.Н., Гребнева И.В. Анализ влияния вакцинопрофилактики пневмококковой инфекции у пациентов с хронической обструктивной болезнью легких в сочетании с сахарным диабетом. Терапевтический архив. 2019;91(11):54-9 [Ignatova GL, Blinova EV, Antonov VN, Grebneva IV. Analysis of the impact of vaccination of pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with diabetes. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(11):54-9 (in Russian)]. doi: 10.26442/00403660.2019.11.000424
  15. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of chronic obstructive lung disease. 2018 report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed: 01.10.2021.
  16. Чучалин А.Г., Айсанов З.Р., Чикина С.Ю., и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014;6:11-24 [Chuchalin AG, Aysanov ZR, Chikina SYu, et al. Federal guidelines of Russian Respiratory Society on spirometry. Pulmonologiya. 2014;6:11-24 (in Russian)]. doi: 10.18093/0869-0189-2014-0-6-11-24
  17. Игнатова Г.Л., Антонов В.Н. Влияние вакцинации на динамику бронхиального и системного воспаления у пациентов с хронической обструктивной болезнью легких и ишемической болезнью сердца. Терапевтический архив. 2017;89(3):29-33 [Ignatova GL, Antonov VN. Impact of vaccination on the course of bronchial and systemic inflammation in patients with COPD and CHD. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(3):29-33 (in Russian)]. doi: 10.17116/terarkh201789329-33
  18. Руководство по клинической иммунологии в респираторной медицине. Под ред. М.П. Костинова, А.Г. Чучалина. 2-е изд. М.: ООО «АТМО», 2018 [Rukovodstvo po klinicheskoi immunologii v respiratornoi meditsine. Pod red. Kostinova MP, Chuchalina AG. 2-e izd. Moscow: ATMO, 2018 (in Russian)].
  19. Celli BR. Predictors of mortality in COPD. Respir Med. 2009;104(6):773-9. doi: 10.1183/09031936.00012408
  20. Decramer M, Janssens W. Chronic obstructive pulmonary disease and Comorbidities. Lancet Respir Med. 2013;1(1):73-83. doi: 10.1016/S2213-2600(12)70060-7
  21. Fabbri LM. Smoking, Not COPD, as the Disease. N Engl Med J. 2016;374(19):1885-6. doi: 10.1056/NEJMe1515508
  22. Rabe KF, Wedzicha JA, Wouters EFM. COPD and Comorbidity. Eur Respir Soc Monograph. 2013;59. doi: 10.1183/1025448x.10000613
  23. Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваний. Руководство для врачей. М.: МДВ, 2009 [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevanii. Rukovodstvo dlia vrachei. Guide for doctors. Moscow: MDV, 2009 (in Russian)].
  24. Clement S, Braithwaite SS, Magel MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553-91. doi: 10.2334/diacare.27.2.553
  25. Жук Е.А. Изменения иммунологических параметров при диабетическом кетоацидозе. Актуальные проблемы современной эндокринологии: Материалы IV Всероссийского конгресса эндокринологов. СПб., 2001; c. 68 [Zhuk EA. Izmeneniia immunologicheskikh parametrov pri diabeticheskom ketoatsidoze. Aktual'nye problemy sovremennoi endokrinologii: Materialy IV Vserossiiskogo kongressa endokrinologov. Saint Petersburg, 2001; p. 68 (in Russian)].
  26. Лысенко Л.В. Диабетическая макро- и микроангиопатия легких. Арх. патологии. 1990;11:31-6 [Lysenko LV. Diabetic macro- and microangiopathy of the lungs. Arch Patologii. 1990;11:31-6 (in Russian)].
  27. Колодова И.М., Лысенко Л.В., Салтыков Б.Б. Изменения в легких при сахарном диабете. Арх. патологии. 1982;7:35-40 [Kolodova IM, Lysenko LV, Saltykov BB. Changes in the lungs in diabetes mellitus. Arch Patologii. 1982;7:35-40 (in Russian)].
  28. Муминоров А.И., Шамирзоев Н.Х., Джаббаров Н.Д. Морфологические исследования слизистой оболочки носовой полости при сахарном диабете. Вестн. отоларингологии. 1980;4:39-42 [Muminorov AI, Shamirzoev NKh, Jabbarov ND. Morphological studies of the nasal mucosa in diabetes mellitus. Vestn Otolaryngologii. 1980;4:39-42 (in Russian)].
  29. Musher DM, Rueda AM, Kaka AS, Mapara SM. The Association between Pneumococcal Pneumonia and Acute Cardiac Events. Clin Infect Dis. 2007;45:158-65. doi: 10.1086/518849
  30. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70:984-9.
  31. Huijts SM, van Werkhoven CH, Bolkenbaas M, et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017;35(34):4444-9. doi: 10.1016/j.vaccine.2017.01.071

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies